Kymriah® is a genetically-modified autologous immunocellular therapy indicated for the treatment of:

• Paediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.
• Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
• Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.